China’s National Medical Products Administration granted AstraZeneca and Merck marketing authorization for Lynparza (olaparib) as a first-line maintenance treatment of adult patients with newly diagnosed advanced germline or somatic BRCA mutated (gBRCAm or sBRCAm) epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. The companies received marketing authorization Dec. 5.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
